DSIP Got Rejected — Here's Where the Sleep Stack Stands
Six peptides walked out of the July FDA meeting with recommendations. DSIP walked out with the only rejection — 6–7, one abstention, a single vote short. For everyone who runs sleep as the foundation of recovery (which should be everyone), here is what the rejection means and where the sleep stack actually stands.
Why DSIP Lost
Delta sleep-inducing peptide was evaluated for opioid withdrawal, chronic insomnia, and narcolepsy. It carried the oldest and weakest human evidence of the seven compounds — small European trials, mostly from the 1980s, with inconsistent results. It was the one case where the committee agreed with FDA staff instead of overriding them. The harm-reduction argument that saved BPC-157 also fit badly here: sleep is not an access desert. Multiple approved, well-characterized treatments already exist, so "compounding beats the bodega" carried less weight.
What the Rejection Does and Does Not Mean
DSIP's legal status is unchanged — it was research-only before July 24 and still is. What it lost is a place in the rulemaking queue. While the six winners wait for possible listing, DSIP is not in line at all, and no re-nomination is scheduled. A one-vote loss is not a scientific verdict against the compound, just as the one-vote-flavored wins were not verdicts for theirs.
The Sleep Angle That Did Win
Quietly, the meeting's actual sleep story was Epitalon — evaluated by the FDA for insomnia, recommended 7–5 on day two. The longevity crowd claims Epitalon for telomeres, but its regulatory pathway, if it ever completes, runs through sleep. If you were watching this meeting for the recovery-sleep implications, Epitalon is the compound that came out with momentum.
Building the Sleep Base Without Waiting on the FDA
Nothing at this meeting changed the hierarchy: the highest-yield sleep interventions remain the unsexy ones — consistent timing, cold and dark, training load management, caffeine cutoffs, and treating diagnosed sleep disorders through an actual physician. If you want prescribed, physician-supervised options that are already legal today, Veritide ranks licensed telehealth providers. On the research side, the compounds under active study are covered in depth at PeptideOnline, including the Epitalon file.
Full meeting scoreboard: the 6-of-7 breakdown.
Partner links. Research compounds are for laboratory use only.
Questions
The committee voted 6-7 with one abstention, agreeing with FDA staff that DSIP's evidence - mostly small, older trials - was the weakest of the seven, and noting insomnia already has multiple approved treatments.
No. Its status is unchanged - research-only, exactly as before the meeting. It simply is not in the queue for potential 503A listing.
Epitalon, which the FDA evaluated for insomnia, was recommended 7-5 on July 24, 2026.
Substances can be renominated for future PCAC review, but no DSIP re-vote is scheduled or signaled.
Approved prescription treatments through licensed physicians and telehealth providers - independent rankings at Veritide.co - plus the foundational behavioral interventions that outperform everything else.